Array BioPharma, VentiRx In License Deal
Boulder, Colorado-based Array BioPharma and San Diego-based VentiRx Pharmaceuticals said this morning that the two companies are in a license agreement. VentiRx has been granted exclusive worldwide rights to Array's Toll-like receptor (TLR) program. Array BioPharma's program targets oncology and allergy therapeutics. Financial terms were not disclosed, however, Array will receive an equity stake in VentiRx plus milestone payments and royalties.
posted on Tuesday, March 13, 2007
Related companies:
Array Biopharma
Related stories:
> Array BioPharma Licenses Rights To Amgen
> Array BioPharma Gets $85M From Novartis
> Array BioPharma Hits Milestone
> Array BioPharma Appoints New CFO
> Array BioPharma Raises $18M From Realty Sale
Techrockies.com Home